Alpha lipoic acid for mild to moderate ulcerative colitis
Part of Digestive system clinical trials.
This trial tests whether adding alpha lipoic acid (an antioxidant) to your usual mesalamine treatment helps control mild to moderate ulcerative colitis. It is for people newly diagnosed and not on other UC treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been newly diagnosed with mild to moderate ulcerative colitis.
- You are currently taking mesalamine (a medicine for UC).
- You do not have severe UC, colorectal cancer, or other inflammatory diseases.
- You do not have diabetes, thyroid disease, heart problems, or significant liver disease.
- You are not taking steroids, immunosuppressants, certain other medications, or antioxidant supplements.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a probiotic supplement and trace elements to your current treatment helps manage mild to moderate ulcerative colitis. It aims to see if these additions can improve symptoms and quality of life.
This study tests adding a medicine called mebendazole (normally used for parasites) to standard mesalamine treatment for people with mild or moderate ulcerative colitis. The goal is to see if it helps control inflammation better than mesalamine alone.
This study tests whether acupuncture can help reduce symptoms like diarrhea and blood in stool for people with mild to moderate ulcerative colitis. It is a non-drug treatment that may be added to your usual therapy with mesalamine.
This study tests an experimental tablet for people with moderate to severe ulcerative colitis that hasn't improved with standard treatments. It aims to see if the tablet can reduce symptoms and inflammation.
This study tests whether adding acupuncture (using small intradermal needles) to the standard medication mesalazine improves outcomes for people with mild-to-moderate ulcerative colitis. Participants receive 12 acupuncture sessions and undergo two colonoscopies to assess the treatment's effect.
This trial tests if adding febuxostat to your usual mesalamine treatment can help improve mild to moderate ulcerative colitis. It's for adults with confirmed UC who are not on steroids or other immune-suppressing drugs.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.